Bupivacaine; Meloxicam Patent Expiration

Bupivacaine; Meloxicam is used for postoperative pain management in various surgical procedures. It was first introduced by Heron Therapeutics Inc in its drug Zynrelef Kit on May 12, 2021.


Bupivacaine; Meloxicam Patents

Given below is the list of patents protecting Bupivacaine; Meloxicam, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zynrelef Kit US10098957 Long-acting polymeric delivery systems Apr 20, 2035 Heron Theraps Inc
Zynrelef Kit US10213510 Long-acting polymeric delivery systems Apr 20, 2035 Heron Theraps Inc
Zynrelef Kit US10398686 Compositions of a polyorthoester and an aprotic solvent Mar 13, 2034 Heron Theraps Inc
Zynrelef Kit US10632199 Long-acting polymeric delivery systems Apr 20, 2035 Heron Theraps Inc
Zynrelef Kit US10898575 Long-acting polymeric delivery systems Apr 20, 2035 Heron Theraps Inc
Zynrelef Kit US10980886 Compositions of a polyorthoester and an organic acid excipient Apr 20, 2035 Heron Theraps Inc
Zynrelef Kit US11083730 Long-acting polymeric delivery systems Apr 20, 2035 Heron Theraps Inc
Zynrelef Kit US11083797 Long-acting polymeric delivery systems Apr 20, 2035 Heron Theraps Inc
Zynrelef Kit US11253504 Compositions of a polyorthoester and an aprotic solvent Mar 13, 2034 Heron Theraps Inc
Zynrelef Kit US11413350 Long-acting polymeric delivery systems Apr 20, 2035 Heron Theraps Inc
Zynrelef Kit US11844837 Compositions of a polyorthoester and an organic acid excipient Apr 21, 2036 Heron Theraps Inc
Zynrelef Kit US9592227 Compositions of a polyorthoester and an aprotic solvent Mar 13, 2034 Heron Theraps Inc
Zynrelef Kit US9694079 Long-acting polymeric delivery systems Apr 20, 2035 Heron Theraps Inc
Zynrelef Kit US9744163 Compositions of a polyorthoester and an aprotic solvent Mar 13, 2034 Heron Theraps Inc
Zynrelef Kit US9801945 Long-acting polymeric delivery systems Apr 20, 2035 Heron Theraps Inc
Zynrelef Kit US9913909 Compositions of a polyorthoester and an aprotic solvent Mar 13, 2034 Heron Theraps Inc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bupivacaine; Meloxicam's patents.

Given below is the list recent legal activities going on the following patents of Bupivacaine; Meloxicam.

Event Date Patent/Publication
Patent litigations
Email Notification 20 Dec, 2023 US11844837
Patent Issue Date Used in PTA Calculation 19 Dec, 2023 US11844837
Mail Patent eGrant Notification 19 Dec, 2023 US11844837
Patent eGrant Notification 19 Dec, 2023 US11844837
Recordation of Patent eGrant 19 Dec, 2023 US11844837
Recordation of Patent Grant Mailed 19 Dec, 2023 US11844837
Email Notification 30 Nov, 2023 US11844837
Issue Notification Mailed 29 Nov, 2023 US11844837
Application Is Considered Ready for Issue 15 Nov, 2023 US11844837
Dispatch to FDC 15 Nov, 2023 US11844837



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳